Compile Data Set for Download or QSAR
maximum 50k data
Found 465 Enz. Inhib. hit(s) with all data for entry = 911
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298092(3-[3-(2-tert-butoxyethyl)-1,2,4-oxadiazol-5-yl]-2-...)
Affinity DataIC50:  6nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298254(3-(2-methylbutanoyl)-7-(piperidin-4-yl)pyrazolo[1,...)
Affinity DataIC50:  8nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298255(3-(cyclopropylcarbonyl)-7-(piperidin-4-yl)pyrazolo...)
Affinity DataIC50:  8nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298041(3-(2-methyl-1,3-thiazol-5-yl)-7-(piperidin-4-yl)py...)
Affinity DataIC50:  8.20nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297950(7-(piperidin-4-yl)-3-{5-[4-(trifluoromethyl)phenyl...)
Affinity DataIC50:  8.70nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298115(7-(piperidin-4-yl)-3-(piperidin-1-ylcarbonyl)pyraz...)
Affinity DataIC50:  9nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298123(3-(4-cyclohexyl-1,3-thiazol-2-yl)-7-(piperidin-4-y...)
Affinity DataIC50:  9nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298009(3-[3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl]-7-(pip...)
Affinity DataIC50:  9.70nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298073(3-[5-(2-phenylethyl)-1,3,4-oxadiazol-2-yl]-7-(pipe...)
Affinity DataIC50:  10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298184(Rel-3-{5-[(1R,2S)-2-methylcyclopentyl]-1,2,4-oxadi...)
Affinity DataIC50:  10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298237(3-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2-met...)
Affinity DataIC50:  10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298246(3-[3-(4-hydroxybenzyl)-1,2,4-oxadiazol-5-yl]-2-met...)
Affinity DataIC50:  10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297791(Ethyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297845(5-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298063(3-[5-(3-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(pip...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298096(2-methyl-3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-y...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298098(3-(4-ethyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyr...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298127(3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2-methyl-7-(...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298161(Cyclobutyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-d...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298170(7-(piperidin-4-yl)-3-(1,2-thiazol-5-yl)pyrazolo[1,...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298253(3-(cyclopentylcarbonyl)-7-(piperidin-4-yl)pyrazolo...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297809(7-(Piperidin-4-yl)-3-(3-propyl-1,2,4-oxadiazol-5-y...)
Affinity DataIC50:  12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297842((−)-trans-7-(2-Methylpiperidin-4-yl)-5-oxo-4...)
Affinity DataIC50:  12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297850(3-(Phenylsulfonyl)-7-(piperidin-4-yl)pyrazolo[1,5-...)
Affinity DataIC50:  12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298037(3-{5-[4-methyl-2-(trifluoromethyl)phenyl]-1,2,4-ox...)
Affinity DataIC50:  12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298114(3-[(3,3-difluoroazetidin-1-yl)carbonyl]-7-(piperid...)
Affinity DataIC50:  12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298238(3-[3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-meth...)
Affinity DataIC50:  12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297797(N-Benzyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyraz...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297808(3-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297824(4-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297837(3-(3-Methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298061(3-(5-methyl-4-phenyl-1,3-thiazol-2-yl)-7-(piperidi...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297796(N-Isobutyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyr...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297798(3-(Morpholin-4-ylcarbonyl)-7-(piperidin-4-yl)pyraz...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297815((−)-trans-3-Chloro-7-(2-methylpiperidin-4-yl...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297825(3-(3-Chlorophenyl)-7-(piperidin-4-yl)pyrazolo[1,5-...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297847(7-(Piperidin-4-yl)-3-[3-(trifluoromethoxy)phenyl]p...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297939(7-(piperidin-4-yl)-3-{3-[2-(trifluoromethoxy)pheny...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298065(3-[5-(2-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(pip...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298154(Methyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazol...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298177(3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-7-(piperidi...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298182(3-(5-Cyclopentyl-1,2,4-oxadiazol-3-yl)-7-(piperidi...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298247(3-[5-(3-fluoro-4-methoxybenzyl)-1,3,4-oxadiazol-2-...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297793(Benzyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazol...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297794(N-Ethyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazo...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297807(3-(3-Methyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-4-y...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297810(3-(3-Phenyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-4-y...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297830(3-(4-Methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297836(7-(Piperidin-4-yl)-3-(2-thienyl)pyrazolo[1,5-a]pyr...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298005(3-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]-7-(pip...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 465 total ) | Next | Last >>
Jump to: